Conatus Pharmaceuticals Inc to Post FY2019 Earnings of $3.72 Per Share, SunTrust Banks Forecasts (CNAT)

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) – Equities research analysts at SunTrust Banks lowered their FY2019 EPS estimates for Conatus Pharmaceuticals in a report issued on Monday. SunTrust Banks analyst J. Boris now forecasts that the biotechnology company will post earnings of $3.72 per share for the year, down from their previous forecast of $3.82. SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ FY2020 earnings at $3.50 EPS and FY2021 earnings at $2.92 EPS.

Several other research firms have also recently commented on CNAT. Aegis reissued a “buy” rating and set a $11.00 target price on shares of Conatus Pharmaceuticals in a research report on Monday, May 15th. Zacks Investment Research cut shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 21st. Stifel Nicolaus reissued a “buy” rating and set a $9.00 target price (up previously from $7.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, March 16th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Conatus Pharmaceuticals in a research report on Friday, March 17th. Finally, FBR & Co reissued an “outperform” rating and set a $16.00 target price on shares of Conatus Pharmaceuticals in a research report on Wednesday, March 15th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $13.25.

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

COPYRIGHT VIOLATION WARNING: This article was posted by sleekmoney and is the property of of sleekmoney. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://sleekmoney.com/conatus-pharmaceuticals-inc-to-post-fy2019-earnings-of-3-72-per-share-suntrust-banks-forecasts-cnat/1849936.html.

Conatus Pharmaceuticals (NASDAQ:CNAT) traded up 0.57% during mid-day trading on Wednesday, reaching $5.33. The company’s stock had a trading volume of 161,612 shares. The company’s market cap is $139.48 million. The firm has a 50 day moving average price of $6.80 and a 200 day moving average price of $4.70. Conatus Pharmaceuticals has a 52-week low of $1.45 and a 52-week high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.20. The business had revenue of $7 million during the quarter, compared to the consensus estimate of $5.88 million. During the same quarter in the prior year, the company earned ($0.35) EPS.

Institutional investors have recently bought and sold shares of the company. Courage Capital Management LLC boosted its position in Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock valued at $721,000 after buying an additional 25,000 shares in the last quarter. Renaissance Technologies LLC boosted its position in Conatus Pharmaceuticals by 28.1% in the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock valued at $1,358,000 after buying an additional 51,590 shares in the last quarter. Morgan Stanley boosted its position in Conatus Pharmaceuticals by 265.6% in the first quarter. Morgan Stanley now owns 67,095 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 48,741 shares in the last quarter. Geode Capital Management LLC boosted its position in Conatus Pharmaceuticals by 21.4% in the first quarter. Geode Capital Management LLC now owns 104,972 shares of the biotechnology company’s stock valued at $605,000 after buying an additional 18,512 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Conatus Pharmaceuticals by 93.1% in the first quarter. Vanguard Group Inc. now owns 767,517 shares of the biotechnology company’s stock valued at $4,428,000 after buying an additional 369,973 shares in the last quarter. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

12 Month Chart for NASDAQ:CNAT

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/conatus-pharmaceuticals-inc-to-post-fy2019-earnings-of-3-72-per-share-suntrust-banks-forecasts-cnat/1849936.html

Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *